$HOOD

Robinhood gets second bullish Wall Street call in two days

Morgan Stanley upgraded Robinhood (HOOD) to Overweight, setting a $150 price target, citing improved revenue per user. Bernstein also reiterated its Outperform rating with a $160 target. Robinhood's Q2 2026 revenue rose 32% YoY to $1.31B, with net income up 48% to $573M. Event contracts and prediction markets revenue surged, while crypto trading revenue fell 38% to $100M, according to the company.

Original reporting
Published Sep 1, 2026, 7:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 1, 2026, 7:34 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Robinhood gets second bullish Wall Street call in two days — source image
Decision brief

The 30-second read

$HOODBullishMed
01

Why it matters

Analyst upgrades reflect confidence in monetization of existing users and new business lines.

02

Market read

Robinhood's stock may rally on fresh analyst optimism and strong Q2 fundamentals.

03

What to watch

Potential regulatory headwinds on crypto and prediction markets could curb growth.

Relevance 7/10Novelty 7/10Timing: today

Background

Robinhood reported Q2 2026 results with 32% revenue growth and record user metrics.

Company-level read

Ticker impact

$HOODBullishHigh confidence
Context

Morgan Stanley upgraded Robinhood to Overweight with a new $150 price target, citing Q2 revenue growth.

Expected impact

Bullish, target suggests near‑term buying interest.

Evidence & confidence

Upgrade and higher target are fresh analyst actions that can drive immediate price movement.

Market effects

Positive for brokerage and fintech sector as upgrade highlights revenue diversification.

U.S. market focus, limited regional effect.

Modest, mainly U.S. retail trading audience.

Counterpoint

Upgrade may be premature if crypto revenue weakness persists.

Key entities

  • Morgan Stanley

    Upgraded Robinhood to Overweight with $150 target.

  • Bernstein

    Reiterated Outperform rating with $160 target.

Related articles

$HOODMed

Morgan Stanley Just Upgraded Robinhood Markets Inc. (HOOD). Here’s Why

Morgan Stanley upgraded Robinhood (HOOD) to Overweight, raising its price target to $150. The firm cites Robinhood's expanding product ecosystem, including prediction markets, as drivers for increased customer revenue. Robinhood's Q2 event-contract volume surged to 13.6 billion, with revenue from these contracts reaching $156 million. However, trading activity remains a key risk due to its significant contribution to revenue.

$HOODHigh

Morgan Stanley Upgrades HOOD, Cites Prediction Market Boom for $150 Target

Morgan Stanley upgraded Robinhood (HOOD) to Overweight, raising its price target to $150 from $124. Analyst Michael Cyprys cited growth in prediction markets, which generated $156M in Q2 revenue. Robinhood's prediction market revenue surpassed stock and crypto trading. Morgan Stanley increased its earnings estimates for 2026-2028 by 12%-15% and expects revenue to grow 23% annually to $8B by 2028.

$HOODHigh

Morgan Stanley upgrades Robinhood stock, raises target to $150

Morgan Stanley upgraded Robinhood (HOOD) to overweight, raising its target to $150 from $124, citing undervalued revenue potential from existing customers. Analyst Michael Cyprys highlighted increased assets, activity, and monetization per customer, along with the company's derivatives exchange, Rothera. The upgrade comes amid falling crypto volumes, with 22 of 28 analysts rating HOOD a buy or strong buy.

$HOODMed

Stocks making the biggest moves premarket: Nvidia, Robinhood, Novartis & more

Premarket movers: Chipmakers fell as Treasury yields rose, with Nvidia, AMD, and Micron down over 1%. Energy stocks climbed over 1% alongside oil prices. Robinhood gained 2% after a Morgan Stanley upgrade. Novartis rose 4% on positive MS drug trial data. Duolingo advanced 6% following an Evercore ISI upgrade. Medtronic gained 5% after raising its fiscal 2027 EPS outlook.